

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/705, 14/715, C12N 15/12		A1	(11) International Publication Number: WO 97/41154
			(43) International Publication Date: 6 November 1997 (06.11.97)
(21) International Application Number: PCT/US97/06568		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 24 April 1997 (24.04.97)			
(30) Priority Data: 08/640,991 26 April 1996 (26.04.96) US 60/016,158 26 April 1996 (26.04.96) US 9700894.0 17 January 1997 (17.01.97) GB		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): DAUGHERTY, Bruce, L. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). DEMARTINO, Julie, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SPRINGER, Martin, S. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SICILIANO, Salvatore, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			
(54) Title: EOSINOPHIL EOTAXIN RECEPTOR			
(57) Abstract <p>The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.</p>			

AN3

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

TITLE OF THE INVENTION

EOSINOPHIL EOTAXIN RECEPTOR

CROSS REFERENCE TO RELATED APPLICATIONS

- 5 This application claims priority under 35 U.S.C. § 119(e) from provisional application Case Number 19634PV, filed April 26, 1996 and from provisional application Case Number 19697PV, filed April 26, 1996 as USSN 60/016,158.

10 FIELD OF THE INVENTION

- This invention relates to an eosinophil eotaxin receptor ("CC CKR3"), in particular, the human eosinophil eotaxin receptor and nucleic acids encoding this receptor. This invention further relates to assays which may be used to screen and identify
- 15 compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

20 BACKGROUND OF THE INVENTION

- Eosinophils play prominent roles in a variety of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma (for a reviews see e.g. Gleich, G. J., et al., *Eosinophils*. J. I. Gallin, I. M. Goldstein, R. Snyderman, Eds.,
- 25 Inflammation: Basic Principles and Clinical Correlates (Raven Press, Ltd., New York, 1992) and Seminario, M. C., et al. (1994) *Current Opinion in Immunology* 6, 860-864). A pivotal event in the process is the accumulation of eosinophils at the involved sites. While a number of the classical chemoattractants, including C5a, LTB4, and PAF, are
- 30 known to attract eosinophils (Gleich, G. J., et al., *Eosinophils*. J. I. Gallin, et al. Eds., Inflammation: Basic Principles and Clinical Correlates (Raven Press, Ltd., New York, 1992)), these mediators are promiscuous, acting on a variety of leukocytes including neutrophils, and are unlikely to be responsible for the selective accumulation of

- 2 -

eosinophils. In contrast, the chemokines a family of 8-10 kDa proteins are more restricted in the leukocyte subtypes they target and are potential candidates for the recruitment of eosinophils in atopic diseases and asthma (Baggiolini, M., Dewald, B. and Moser, B. (1994) *Advances in Immunology* **55**, 97-179). Although there is a mounting body of evidence that eosinophils are recruited to sites of allergic inflammation by a number of β -chemokines, particularly eotaxin and RANTES, the receptor which mediates these actions has not been identified.

The chemokines contain four conserved cysteines, and are divided into two sub-families based on the arrangement of the first cysteine pair (Baggiolini, M., Dewald, B. and Moser, B. (1994) *Advances in Immunology* **55**, 97-179). In the α -chemokine family, which includes IL-8, MGSA, NAP-2 and IP-10, these two cysteines are separated by a single amino acid, while in the β -chemokine family, which includes RANTES ("regulated on activation T expressed and secreted"), MCP-1 ("monocyte chemotactic protein"), MCP-2, MCP-3, MIP-1 α ("macrophage inflammatory protein"), MIP-1 β and eotaxin, these two cysteines are adjacent. There is a functional correlate to this structural division. The α -chemokines act primarily on neutrophils, and the β -chemokines on monocytes, lymphocytes, basophils and eosinophils (Baggiolini, M., Dewald, B. and Moser, B. (1994) *Advances in Immunology* **55**, 97-179). In particular, RANTES, MCP-2, MCP-3, and MIP-1 α have been shown to activate eosinophils in vitro (Dahinden, C. A., et al. (1994) *Journal of Experimental Medicine* **179**, 751-756; Ebisawa, M., et al. (1994) *Journal of Immunology* **153**, 2153-2160; Weber, M., et al. (1995) *Journal of Immunology* **154**, 4166-4172), and RANTES to selectively attract eosinophils in vivo (Meurer, R., et al. (1993) *Journal of Experimental Medicine* **178**, 1913-1921; Beck, L., et al. (1995) *FASEB Journal* **9**, A804). Similarly, eotaxin, a new member of the β -chemokine family, first described in guinea pigs (Griffiths-Johnson, D. A., et al. (1993) *Biochemical and Biophysical Research Communications* **197**, 1167-1172; Jose, P. J., et al. (1994) *Journal of Experimental Medicine* **179**, 881-887) and mice (Rothenberg, et al. (1995) *Proceedings of the National Academy of*

- 3 -

- Sciences* 92, 8960-8964) is also a potent attractant and activator of eosinophils both in vitro and in vivo. Moreover, eotaxin is generated during antigenic challenge in the guinea pig model of allergic airway inflammation (Jose, et al. (1994) *J. Exp. Med.*, 179, 881-887;
- 5 Rothenberg, et al. (1995) *J. Exp. Med.*, 181, 1211-1216. The cloning of guinea pig eotaxin has been disclosed (PCT Patent Publication No. WO 95/07985; March 23, 1995). The cloning of the human eosinophil chemoattractant eotaxin has recently been reported (Ponath, et al., *J. Clin. Invest.* (1996) 97(3) 604-612) and eotaxin has been suggested to
- 10 be a very important agent in the mechanism of allergic inflammation (Baggiolini, et al., *J. Clin. Invest.* (1996) 97(3) 587).

- Eosinophils are attracted by a number of β -chemokines, the most potent of which are eotaxin (Griffiths-Johnson, D. A., et al. (1993) *Biochemical and Biophysical Research Communications* 197, 1167-
- 15 1172; Jose, P. J., et al. (1994) *Journal of Experimental Medicine* 179, 881-887; Rothenberg, et al. (1995) *Proceedings of the National Academy of Sciences* 92, 8960-8964) and RANTES (Dahinden, C. A., et al. (1994) *Journal of Experimental Medicine* 179, 751-756; Ebisawa, M., et al. (1994) *Journal of Immunology* 153, 2153-2160;
- 20 Weber, M., et al. (1995) *Journal of Immunology* 154, 4166-4172; Meurer, R., et al. (1993) *Journal of Experimental Medicine* 178, 1913-1921; Beck, L., et al. (1995) *FASEB Journal* 9, A804). Although several human
- β -chemokine receptors have been characterized in detail, none have the
- 25 appropriate selectivity to account for the observed responses.

- While elucidation of the actions of β -chemokines on eosinophils has contributed greatly to the understanding of eosinophil biology, information regarding the cell surface receptors which mediate these effects remain sparse. Furthermore, there are no reports
- 30 describing binding studies of any of the β -chemokines to primary eosinophils. The known β -chemokine receptors are members of the G protein-coupled receptor superfamily. Two of these receptors, CC CKR1 (12, 13) and CC CKR2 (MCP-1R) (Charo, I. F., et al. (1994) *Proceeding of the National Academy of Sciences* 91, 2752-2756;

- 4 -

Myers, S. J., et al. (1995) *Journal of Biological Chemistry* **270**, 5786-5792; Franci, C., et al. (1995) *Journal of Immunology* **154**, 6511-6517) found on monocytes, have been extensively studied and their selectivity for the different chemokines defined. However, neither of
5 these receptors has the necessary ligand selectivity or the appropriate expression patterns required to mediate the effects of the β -chemokines on eosinophils. For example, CC CKR1 binds RANTES with high affinity, but binds eotaxin poorly, and while the effects of eotaxin on CC CKR2 have not been studied this receptor has no avidity for
10 RANTES (Myers, S. J., et al. (1995) *Journal of Biological Chemistry* **270**, 5786-5792).

A review of the role of chemokines in allergic inflammation is provided by Kita, H., et al., *J. Exp. Med.* **183**, 2421-2426 (June 1996). In particular, this review discusses the role which
15 the receptor CKR-3 plays in the process of allergic inflammation. The cloning, expression and characterization of the human eosinophil eotaxin receptor has been reported by Daugherty, B.J., et al., *J. Exp. Med.* **183**, 2349-2354 (May 1996). This publication discloses the cloning and functional expression of the chemokine receptor CC CKR3,
20 as well as its characterization.

The cloning and expression of a human eosinophil receptor was allegedly achieved by Combadiere, C., et al., *J. Biological Chem.* **270** (27), 16491-16494 (July 14, 1995). However, in a subsequent retraction (*J. Biological Chem.* **270**, 30235 (1995)) they confirmed that
25 the receptor which was actually cloned and expressed was not CC CKR3, but was another CC chemokine receptor CC CKR5. This receptor was subsequently characterized by Kitaura, M., et al., *J. Biological Chem.* **271** (13), 7725-7730 (March 29, 1996).

A human eotaxin receptor has been reported by Ponath, P.D., et al. *J. Exp. Med.* **183**, 2437-2448 (June 1996) and Gerard, C.J., et al., *PCT Publication No. WO 96/22371* (July 25, 1996). However,
30 the sequence disclosed in this publication possesses an error in the assignment of threonine rather than serine at position # 276 of the

- 5 -

receptor. In addition, functionality of the receptor was not fully demonstrated.

A retrovirus designated human immunodeficiency virus (HIV-1) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. Entry of HIV-1 into a target cell requires cell-surface CD4 and additional host cell cofactors. Fusin has been identified as a cofactor required for infection with virus adapted for growth in transformed T-cells, however, fusin does not promote entry of macrophagetropic viruses which are believed to be the key pathogenic strains of HIV in vivo. It has recently been recognized that for efficient entry into target cells, human immunodeficiency viruses require the chemokine receptors CCR-5 and CXCR-4, as well as the primary receptor CD4 (Levy, *N. Engl. J. Med.*, 335(20), 1528-1530 (Nov. 14 1996). The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-trophic strains of HIV-1 is CCR5, a receptor for the β -chemokines RANTES, MIP-1 α and MIP-1 β (Deng, et al., *Nature*, 381, 661-666 (1996)). HIV attaches to the CD4 molecule on cells through a region of its envelope protein, gp120. It is believed that the CD-4 binding site on the gp120 of HIV interacts with the CD4 molecule on the cell surface, and undergoes conformational changes which allow it to bind to another cell-surface receptor, such as CCR5 and/or CXCR-4. This brings the viral envelope closer to the cell surface and allows interaction between gp41 on the viral envelope and a fusion domain on the cell surface, fusion with the cell membrane, and entry of the viral core into the cell. It has been shown that β -chemokine ligands prevent HIV-1 from fusing with the cell (Dragic, et al., *Nature*, 381, 667-673 (1996)). It has further been demonstrated that a complex of gp120 and soluble CD4 interacts specifically with CCR-5 and inhibits the binding of the natural CCR-5 ligands MIP-1 α and MIP-1 β (Wu, et al., *Nature*, 384, 179-183 (1996); Trkola, et al., *Nature*, 384, 184-187 (1996)).

- 6 -

Humans who are homozygous for mutant CCR-5 receptors which do not serve as co-receptors for HIV-1 in vitro appear to be unusually resistant to HIV-1 infection and are not immunocompromised by the presence of this genetic variant (Nature, 382, 722-725 (1996)).

5 Absence of CCR-5 appears to confer protection from HIV-1 infection (Nature, 382, 668-669 (1996)). Other chemokine receptors may be used by some strains of HIV-1 or may be favored by non-sexual routes of transmission. Although most HIV-1 isolates studied to date utilize CCR-5 or fusin, some can use both as well as the related CCR-2B and
10 CCR-3 as co-receptors (Nature Medicine, 2(11), 1240-1243 (1996)). The determination that chemokine receptors are critical co-receptors for the entry of HIV into cells was pronounced a "1996 Breakthrough of the Year" by Science Magazine (Science, 274, 1987-1991 (Dec. 20, 1996)).

15 The use of orally-active agents which modulate the action of the eosinophil eotaxin receptor would be a significant advance in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma. Further, agents which could block the eosinophil eotaxin receptor in humans who
20 possess normal chemokine receptors should prevent infection in healthy individuals and slow or halt viral progression in infected patients.

It would also be desirable to know the molecular structure of the eosinophil eotaxin receptor in order to analyze this new receptor family and understand its normal physiological role.

25 This could lead to a better understanding of the *in vivo* processes which occur upon ligand-receptor binding. Further, it would be desirable to use cloned-eosinophil eotaxin receptor as essential components of an assay system which can identify new agents for the treatment and prevention of atopic conditions.

30

SUMMARY OF THE INVENTION

The present invention relates to a novel receptor which is the eosinophil eotaxin receptor. This receptor is a human

- 7 -

5 β -chemokine receptor and has been designated "CC CKR3". One aspect of the present invention is directed to the human eosinophil eotaxin receptor, free from receptor-associated proteins. A further aspect of this invention is the human eosinophil eotaxin receptor which is isolated or purified.

Another aspect of this invention are eosinophil eotaxin receptors which are encoded by substantially the same nucleic acid sequences, but which have undergone changes in splicing or other RNA processing-derived modifications or mutagenesis induced changes, so that the expressed protein has a homologous, but
10 different amino acid sequence from the native forms. These variant forms may have different and/or additional functions in human and animal physiology or *in vitro* in cell based assays.

The present invention further provides the eosinophil eotaxin receptor, CC CKR3, which is a β -chemokine receptor and which
15 was cloned from primary eosinophils, and expressed in AML14.3D10 cells. This receptor binds the potent eosinophil attractants, eotaxin, RANTES and MCP-3 with high affinity. In addition, eotaxin and RANTES, and to a lesser extent MCP-3, induce Ca^{2+} -fluxes in cells
20 expressing CC CKR3. Correlation with the binding properties of primary eosinophils provide conclusive evidence that CC CKR3 is the primary endogenous receptor which mediates the effects of β -chemokines on eosinophils.

The present invention further relates to assays which
25 employ a novel receptor which is the eosinophil eotaxin receptor. This receptor is a human β -chemokine receptor and has been designated "CC CKR3". One aspect of the present invention is directed to assays employing the the human eosinophil eotaxin receptor, free from receptor-associated proteins. A further aspect of this invention is
30 directed to assays which employ the human eosinophil eotaxin receptor which is isolated or purified. In addition, the present invention provides assays in which the eosinophil eotaxin receptor is expressed in an AML14.3D10 cell line.

- 8 -

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to an eosinophil eotaxin receptor "CC CKR3" which is a G protein-coupled receptor and has been cloned from human eosinophils and which when stably expressed in AML14.3D10 cells binds eotaxin, RANTES and MCP-3 with high affinity. Competition binding studies against ^{125}I -human eotaxin gives K_d values of 0.1, 2.7, and 3.1 nM, respectively for the three β -chemokines. CC CKR3 also binds MCP-1 with lower affinity, but does not bind MIP-1 α or MIP-1 β . Eotaxin, RANTES, and to a lesser extent MCP-3, but not the other chemokines activate CC CKR3 as determined by the ability to stimulate a Ca^{2+} -flux in clones expressing the receptor. Competition binding studies on primary eosinophils give binding affinities for the different chemokines which are indistinguishable from those measured with CC CKR3. Since CC CKR3 is prominently expressed in eosinophils it is concluded that CC CKR3 is the eosinophil eotaxin receptor. Eosinophils also express a much lower level of a second chemokine receptor, CC CKR1, which appears to be responsible for the effects of MIP-1 α .

The eosinophil eotaxin receptor is a protein containing various functional domains, including one or more domains which anchor the receptor in the cell membrane, and at least one ligand binding domain. As with many receptor proteins, it is possible to modify many of the amino acids, particularly those which are not found in the ligand binding domain, and still retain at least a percentage of the biological activity of the original receptor. In accordance with this invention, it is suggested that certain portions of the eosinophil eotaxin receptor are not essential for its activation by β -chemokines. Thus this invention specifically includes modified functionally equivalent eosinophil eotaxin receptors which have deleted, truncated, or mutated portions. This invention also specifically includes modified functionally equivalent eosinophil eotaxin receptors which contain modified and/or deletions in other domains, which are not accompanied by a loss of functional activity.

- 9 -

5 Additionally, it is possible to modify other functional domains such as those that interact with second messenger effector systems, by altering binding specificity and/or selectivity. Such functionally equivalent mutant receptors are also within the scope of this invention.

10 A further aspect of this invention are nucleic acids which encode an eosinophil eotaxin receptor or a functional equivalent from human or other species. These nucleic acids may be free from associated nucleic acids, or they may be isolated or purified. For most cloning purposes, cDNA is a preferred nucleic acid, but this invention specifically includes other forms of DNA as well as RNAs which encode an eosinophil eotaxin receptor or a functional equivalent.

15 Yet another aspect of this invention relates to vectors which comprise nucleic acids encoding an eosinophil eotaxin receptor or a functional equivalent. These vectors may be comprised of DNA or RNA; for most cloning purposes DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage and cosmids, yeast artificial chromosomes and other forms of episomal or integrated DNA that can encode an eosinophil eotaxin receptor. It is well within the skill of the ordinary artisan to determine an appropriate vector for a particular gene transfer or other use.

25 A further aspect of this invention are host cells which are transformed with a gene which encodes an eosinophil eotaxin receptor or a functional equivalent. The host cell may or may not naturally express an eosinophil eotaxin receptor on the cell membrane. Preferably, once transformed, the host cells are able to express the eosinophil eotaxin receptor or a functional equivalent on the cell membrane. Depending on the host cell, it may be desirable to adapt the DNA so that particular codons are used in order to optimize expression. Such adaptations are known in the art, and these nucleic acids are also included within the scope of this invention.

- 10 -

The receptors of this invention were cloned from RNA isolated from eosinophils. Degenerate PCR was used with primers designed from both CCCR1 and CCCR2, and clones screened by expression in the AML14.3D10 cell line. The cloning was made
5 difficult by several factors. First, prior to this invention there was very little information available about the biochemical characteristics and intracellular signalling/effector pathways used by these receptors making screening procedures uncertain. Second, this receptor could not be expressed and/or functionally coupled in the cell lines
10 normally used for cloning receptors such, as COS, CHO, HEK293. After repeated failures using standard lines, an obscure eosinophilic-like cell line, AML14.3D10, was tried and found to suitable for expression of the receptors described in this invention.

The present invention further relates to assays which
15 employ a novel receptor which is the eosinophil eotaxin receptor. This receptor is a human β -chemokine receptor and has been designated "CC CKR3". One aspect of the present invention is directed to assays employing the the human eosinophil eotaxin receptor, free from receptor-associated proteins. A further aspect of
20 this invention is directed to assays which employ the human eosinophil eotaxin receptor which is isolated or purified. In addition, the present invention provides assays in which the eosinophil eotaxin receptor is expressed in an AML14.3D10 cell line.

25 A particular embodiment of this invention is directed to an assay to determine the presence of a compound which binds to the eosinophil eotaxin receptor. Thus, this invention also comprises a method to determine the presence of a compound which binds to an eosinophil eotaxin receptor comprising:

30 (a) introducing a nucleic acid which encodes an eosinophil eotaxin receptor into a cell under conditions so that eosinophil eotaxin receptor is expressed;

(b) introducing a detector molecule or a nucleic acid encoding a detector molecule into the cell, wherein the detector

- 11 -

molecule is directly or indirectly responsive to a eosinophil eotaxin-ligand binding event;

(c) contacting the cell with a compound suspected of binding to the eosinophil eotaxin receptor; and

5 (d) determining whether the compound binds to the eosinophil eotaxin receptor by monitoring the detector molecule.

In a preferred embodiment of the present invention, the eosinophil eotaxin receptor is expressed in AML14.3D10 cells.

10 In another preferred embodiment of the present invention, the binding of the compound suspected of binding to the eosinophil eotaxin receptor is compared to the binding or the influence of eotaxin, RANTES and MCP-3.

A further embodiment of this invention is directed to an assay to determine the presence of a compound which antagonizes the binding of a known ligand to the eosinophil eotaxin receptor. Thus, this
15 invention further comprises a method to determine the presence of a compound which antagonizes the eosinophil eotaxin receptor comprising:

(a) introducing a nucleic acid which encodes the eosinophil eotaxin receptor into a cell under conditions so that
20 eosinophil eotaxin receptor is expressed;

(b) introducing a detector molecule or a nucleic acid encoding a detector molecule into the cell, wherein the detector molecule is directly or indirectly responsive to an eosinophil eotaxin-ligand antagonism event;
25

(c) contacting the cell with a compound suspected of antagonizing the eosinophil eotaxin receptor;

(d) contacting the cell with a compound which is a known ligand of the eosinophil eotaxin receptor; and

30 (e) determining whether the compound antagonizes the action of the known ligand to the eosinophil eotaxin receptor by monitoring the detector molecule.

- 12 -

In a preferred embodiment of the present invention, the eosinophil eotaxin receptor is expressed in AML14.3D10 cells.

In another preferred embodiment of the present invention, the known ligand of the eosinophil eotaxin receptor is eotaxin, RANTES
5 and MCP-3.

One aspect of this invention is the development of a sensitive, robust, reliable and high-throughput screening assay which may be used to detect ligands which bind to the eosinophil eotaxin receptor, in particular, antagonists of the action of chemokines on
10 eosinophils.

In particular, a typical protocol of such an assay is as follows. Assay buffer (50 mM Hepes, pH 7.2 w/ 0.5% BSA, 5 mM MgCl₂, 1 mM CaCl₂, 100 uM PMSF and 10 ug/ml phosphoramidon, leupeptin, aprotinin and chymostatin), test compound (or equivalent
15 volume of solvent), 20 pM ¹²⁵I-human eotaxin (2000 Ci/mmol), 25 ng unlabeled human eotaxin (non-specific binding wells only), and AML14.3D10 cells expressing eotaxin receptor cells, or eosinophils, are added sequentially in 96-well, round-bottom, polystyrene plates to a final volume of 250 uL. Assay plates are then mixed and incubated for
20 60 minutes at 31°C. After incubation, assay plates are harvested onto Packard 96-well GF/C Unifilter plates treated with 0.33% polyethylenimine (PEI) using Packard Filtermate 196 cell harvester. Wells and filters are washed with 200 uL 50 mM Hepes, pH 7.2 with 0.5M NaCl and 0.02% NaN₃. After filtration, GF/C plates are dried
25 and sealed. 25 uL Packard Microscint-O scintillant are then added to each well and counted for 2 minutes on Packard Topcount (liquid ¹²⁵I setting).

Ligands detected using assays described herein may be used in the treatment and prevention of conditions which would be benefited
30 by the modification of the activity of the eosinophil eotaxin receptor, such as in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

- 13 -

A further aspect of this invention is directed to novel ligands which are identified using the subject assays.

The eosinophil eotaxin receptor and fragments are immunogenic. Thus, another aspect of this invention is antibodies
5 and antibody fragments which can bind to eosinophil eotaxin receptor or an eosinophil eotaxin receptor fragment. These antibodies may be monoclonal antibodies and produced using either hybridoma technology or recombinant methods. They may be used as part of assay systems or to deduce the function of an eosinophil
10 eotaxin receptor present in a cell.

A further aspect of this invention are antisense oligonucleotides nucleotides which can bind to eosinophil eotaxin receptor nucleotides and modulate receptor function or expression.

A further aspect of this invention is a method of
15 increasing the amount of eosinophil eotaxin receptor in a cell comprising, introducing into the cell a nucleic acid encoding an eosinophil eotaxin receptor, and allowing expression of the eosinophil eotaxin receptor.

As used throughout the specification and claims, the
20 following definitions shall apply:

Ligand-- any molecule which binds to an eosinophil eotaxin receptor of this invention. These ligands can have either agonist, partial agonist, partial antagonist or antagonist activity.

Free from receptor-associated proteins-- the receptor
25 protein is not in a mixture or solution with other membrane receptor proteins.

Free from associated nucleic acids-- the nucleic acid is not covalently linked to DNA which it is naturally covalently linked in the organism's chromosome.

30 Isolated receptor-- the protein is not in a mixture or solution with any other proteins.

Isolated nucleic acid-- the nucleic acid is not in a mixture or solution with any other nucleic acid.

- 14 -

Functional equivalent-- a receptor which does not have the exact same amino acid sequence of a naturally occurring eosinophil eotaxin receptor, due to alternative splicing, deletions, mutations, or additions, but retains at least 1%, preferably 10%, and
5 more preferably 25% of the biological activity of the naturally occurring receptor. Such derivatives will have a significant homology with the natural eosinophil eotaxin receptor and can be detected by reduced stringency hybridization with a DNA sequence obtained from an eosinophil eotaxin receptor. The nucleic acid
10 encoding a functional equivalent has at least about 50% homology at the nucleotide level to a naturally occurring receptor nucleic acid.

Purified receptor-- the receptor is at least about 95% pure.
Purified nucleic acid-- the nucleic acid is at least about 95% pure.

Single-letter abbreviations for amino acid residues are as
15 follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

Orphan Cloning of an Eosinophil Chemokine Receptor

20 RT/PCR conducted using oligonucleotide primers developed from the amino acid residues clustered within transmembrane helices II (TMII) and VII (TMVII) of the β -chemokine receptors, CC CKR1 (Neote, K., et al. (1993) *Cell* **72**, 415-425) and MCP-1R (Charo, I. F., et al. (1994) *Proceeding of the National Academy of Sciences* **91**,
25 2752-2756) on total RNA isolated from eosinophils yielded DNA fragments of ~700 bases, a size consistent with that expected for a G protein coupled receptor. Analysis of several TMII to TMVII clones provided a novel sequence which was 76% homologous with human CC CKR1 at the nucleic acid level. Completion of the cloning of the 3' and
30 5' ends gave a sequence for a protein of 355 residues in length, 63% identical to CC CKR1, and 51% identical to CC CKR2B, its closest homologues.

- 15 -

The amino acid sequence of the human eosinophil eotaxin receptor CC CKR3 is depicted below (SEQ ID NO:1):

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser
5 Tyr Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg
Ala Leu Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe
Thr Val Gly Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile
Lys Tyr Arg Arg Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn
Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu Pro Phe Trp
10 Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His Gly Met
Cys Lys Leu Leu Ser Gly Phe Tyr His Thr Gly Leu Tyr Ser Glu
Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile
Val His Ala Val Phe Ala Leu Arg Ala Arg Thr Val Thr Phe Gly
Val Ile Thr Ser Ile Val Thr Trp Gly Leu Ala Val Leu Ala Ala
15 Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu Leu Phe Glu Glu
Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val Tyr Ser Trp
Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu Val Leu
Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys Thr
Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu
20 Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr
Asn Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly
Asn Asp Cys Glu Arg Ser Lys His Leu Asp Leu Val Met Leu Val
Thr Glu Val Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile
Tyr Ala Phe Val Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe
25 Phe His Arg His Leu Leu Met His Leu Gly Arg Tyr Ile Pro Phe
Leu Pro Ser Glu Lys Leu Glu Arg Thr Ser Ser Val Ser Pro Ser
Thr Ala Glu Pro Glu Leu Ser Ile Val Phe

- 16 -

The sequence for the cDNA encoding the human eosinophil eotaxin receptor CC CKR3 beginning with nucleotide 3587 and ending with nucleotide 4651 is depicted below (SEQ ID NO:2):

```
5                                     ATGA CAACCTCACT
3601 AGATACAGTT GAGACCTTTG GTACCACATC CTACTATGAT GACGTGGGCC
3651 TGCTCTGTGA AAAAGCTGAT ACCAGAGCAC TGATGGCCCA GTTTGTGCCC
10 3701 CCGCTGTACT CCCTGGTGTG CACTGTGGGC CTCTGGGCA ATGTGGTGGT
3751 GGTGATGATC CTCATAAAAT ACAGGAGGCT CCGAATTATG ACCAACATCT
15 3801 ACCTGCTCAA CCTGGCCATT TCGGACCTGC TCTTCCTCGT CACCCTTCCA
3851 TTCTGGATCC ACTATGTCAG GGGGCATAAC TGGGT'TTTTG GCCATGGCAT
3901 GTGTAAGCTC CTCTCAGGGT TTTATCACAC AGGCTTGAC AGCGAGATCT
20 3951 TTTTCATAAT CCTGCTGACA ATCGACAGGT ACCTGGCCAT TGTCCATGCT
4001 GTGTTTGCCC TCGAGCCCG GACTGTCACT TTTGGTGTC TCACCAGCAT
25 4051 CGTCACCTGG GGCCTGGCAG TGCTAGCAGC TCTTCCTGAA TTTATCTTCT
4101 ATGAGACTGA AGAGTTGTTT GAAGAGACTC TTGCACTGC TCTTTACCCA
4151 GAGGATACAG TATATAGCTG GAGGCATTTC CACACTCTGA GAATGACCAT
30 4201 CTTCTGTCTC GTTCTCCCTC TGCTCGTTAT GGCCATCTGC TACACAGGAA
4251 TCATCAAAAC GCTGCTGAGG TGCCCCAGTA AAAAAAAGTA CAAGGCCATC
35 4301 CGGCTCATTT TTGTCATCAT GGCGGTGTTT TTCATTTTCT GGACACCCTA
4351 CAATGTGGCT ATCCTTCTCT CTTCTATCA ATCCATCTTA TTTGGAAATG
4401 ACTGTGAGCG GAGCAAGCAT CTGGACCTGG TCATGCTGGT GACAGAGGTG
40 4451 ATCGCCTACT CCCACTGCTG CATGAACCCG GTGATCTACG CCTTTGTTGG
4501 AGAGAGGTTC CGGAAGTACC TGCGCCACTT CTTCCACAGG CACTTGCTCA
45 4551 TGCACCTGGG CAGATACATC CCATTCCTTC CTAGTGAGAA GCTGGAAAGA
4601 ACCAGCTCTG TCTCTCCATC CACAGCAGAG CCGGAACCTCT CTATTGTGTT
50 4651 T
```

or a degenerate variation thereof.

- 17 -

The 5' genomic DNA flanking sequence encoding the human eosinophil eotaxin receptor further comprises the region beginning with nucleotide 1 and ending with nucleotide 3586 as depicted below (SEQ ID NO:3):

```
5      1  GGATCCCTAC CTTCCCCATC AGAGCTAGGG GGCATGGAGC GCTCTCTGCT
      51  AAGATGGGGA CCCCCAAGGA ATGTCTCCCT GTGGGGCACT TCCTTACCAG
10     101  ATGGGATGGC CAGTGGCGTT AAGTTGGTGG TCAGGCAGAA AAAAAAGATC
      151  TAGTTTGTAC TCTTGAGAGT TCCTCGGTTT GTTCATGGCA TGGGCAGGGA
      201  GTCAAGGAGC AGCAGCCTTG CCTCAGTGCC TACCAGTGCA GGAAAAGGTG
15     251  CATAGCCTGG GCCAGGGCCA GGGCCCTGGT GGAGGCGTAG TGGAACAGA
      301  GAGGGCTCTC CATTCCAGCC CAAGGAAGAC TAAGAATGAA TACCTCATGA
20     351  GTATATTAGC TACAAACCAC CACAGCAGGT TCCAGAAAAA GGCTCAGCGT
      401  TGGAACCAGG TCACCCCCAC TCAGCAGACA CCAGTCATAT AAATCAAGGA
      451  CCAACAGGAG ACAGGAACAC CCCCTTCCCA CTCTGCCCCA TGTCTCAAGT
25     501  TGTAAGTGGC CTTCTCTCCAG ATCTCTGCCA CCATCTTAGA AAGGAACACT
      551  GAAAGAAGAA ACTGAAATTA TAAGCTGACA GCATAAAGAG GATGAGTAAA
30     601  ACCTAAAATC ATTGTTTACA TGAATGAATC AAGAGAAGTT TAAACCACCT
      651  TGGACTAAAA TGTGTGAATC CTTTTTCTCTG CTATCCAGCA GATGAGAAGC
      701  TGGTAACAGA GACCACAATA GTTTGGAGAC TAAAGAATCA TTGCACATTT
35     751  CACTGCTGAG TTGTATTGTG AGTAATTTTA GTTGACCTCA CTTTGTAAAT
      801  CTTGCACACG GGGCAATCCA ATATCTGCAC AAGAGATATG TTAACCAGTG
40     851  GTAAATGCTG CATGAGGAGA TTGGGTGATT TTTACTTTCTG TTTTGTGCT
      901  CTTCTTTCTT ATTGTTCTTA CTTATTTACG ATTACCCTAT CGTTTTCCCA
      951  AAATGTAAAA GGCCATTTTG AAAGCCTAAT TCAAACCTCT TCACTATTTT
45    1001  GTATCTAAGT ATTCACCTTG ATTGAGACTG GGTAGACAGG TGAAAACCAT
      1051  ATCAGGTTTT TAATTTTTTA ATTTTAAATT ATTTATTTAT TTATTTATTT
50    1101  TTTGAGATGG AGTCTGGCTG TCGCCCAGGC TGGAGTGCAG CGGCGTGATC
      1151  ACAGTTCACT GCAGCCTCAA CCTTCTAGGC TCAAGGGATT CTCCACCTC
```

- 18 -

1201 AGCCCCCAA GTAGTTGGGA CCACACGTAT GCGCCACCAT GCCTGGCTAA
1251 TTTCTTATTT TTTTGTAGAG ATAGGATCTC ACTATATTGT CCAGGCTGGT
5 1301 CTTGAATTCC TGGGCTCAGG TGAGCCTCCC ACCTGGGCCCT CCCAAAGTAC
1351 TGGGATTACA GGCATGAGCC AAGGTCCCCT GCCCATATGA GATTTTCTGT
10 1401 CTCTGATCCC ATGCAGCTAG TAATCAAGGA CTTGGCTGCT GACTCTGGAG
1451 GACCTGCATG CTTTCTTGAG CTGTGAACTT CAGTGCTAAA AGCTCATAGG
1501 CAGCCCTGAA ACCCAAACCA AAAGGTTCTA TGGTTTATCA TCCTGATCAT
15 1551 GTTGATTTTA TAGAAATAAC ACATGAATTA AAGACACTAC CCTCAAAC TG
1601 AGCAAACTT AAGTAATTTT TTTAAAGTTT GACCTGTTTT TAAATCACTC
1651 TTGGAGAAAA AGGAAAATAA ATACAAATAA TTAACGGTGA ATACAGGCTA
20 1701 CTATACCTTT GTTCTCCAGA ATTAGCAGTT CTGTTCTTTT CTTGCTTTAG
1751 ATGCTGAAGT GCAGAAGGAC ACTCTGTGAT TGTACGTGTG TAACTGACAA
25 1801 AATGTGTATT TTTTCTCTCA GCTGCTATGG ATTGGATTAT GCTATTATGA
1851 ATAAGAATGC TGATGGGAGC ACACACAAAC CATTTGTTCC TCAGTCCATT
1901 TTCCTCCTCA AAAGCCTGGA ATGTGCCATT GATCAGTGGG AGATGTACCT
30 1951 GGACAGACCC ATGAAAAGAG ATCAACAAGT TCCACCCAAG GGACCCTATT
2001 TTTCTTAATT TCATTTGAAA TGGCTTCTAA TTGTCCTTCT TTCATTCCTG
35 2051 CTTCTTACCA GTTTTACAGC TTTTCTGCTT TTTCAAATGTG AACTCACATA
2101 CACTCTCATT TTTCTCTCATC ACAACCCCAA GTGACCCAAT GGTCTCACT
2151 TTCGATATAA GTAAAGGAGG CTCTGCATTA AGGGCTTGTC CAAGGCACGC
40 2201 AGCTGAGAGG CGCTAGGACT GGCTCCATTT CCATCTCTAT TCTCACTGAC
2251 TTTGACTACC CAGAACCCCA ACATGTGGGG CCTCAGTATT CGATCAATTA
45 2301 TTCTATTAAG AAGCAAAAAC AATCCCCGC ATTGGCCCCA GTTATTAAGC
2351 ATTTCTCAGA TTTACCTTGA GAAATGCCCA TCGGCCTGTA TATTACATC
2401 TTCACCCTTG TCCCTTCCTC CTAGAAAGGA GAAAGTCAGT TGGATGCCCT
50 2451 CTGAGGAACT AGTGCATGGC TTAAGTGTCC TTCCATGACT CCTGCCTTAT
2501 CTGTTTTCTA TTTCTCTCCT TTTCCACCGA AGTCTATAAT CTCAAGAAAA
55 2551 GCAGGCACTG GCCTTAGGGC TCCTGGCCTA AGAAATATCA AGTCCAGTGA

- 19 -

2601 GAAATCCCAT TGA CTGACCC CTCCTGCTTA CCCCTTTGTG ATGGAGAAGC
2651 TCCCAGGGGT TTGCTTTTTG CATGTTACCA GGCCTAACTC AGCATCACCA
5 2701 GGGGCAAGAA AAGGAAAGTA ACCTAAACTA ATGCTGCTTA TAATTGTAAT
2751 TATTGTAATA GTTAATTACT GTGATTGTAC ATGTGTAACA GACAAAATGT
10 2801 GTATTTTTTT CACAGCTGCT GTGGATTGGA TTATGCCATT TGGAAATAAGA
2851 ATGCTGTAA GAGCACACAA GCCAGGTTC TCAAGTCCGT AGCAAATTTT
2901 TCAAAAGTTA AATTTAAAAA TCACTACATT TGAATCTAGT GACAGGAGAA
15 2951 ATGGACATGG ATAGAGACTA AAGATCTAGC CCAAATTTTA TATTTACTTG
3001 TTAGAGGATT TTGAACAAAT TACTAAATT CTTCAGGTT CAATTTCCCC
20 3051 ATTA ACTATA ATGAATGTCT CATCATTATG GGGCCCTGGA GAAGCATAAT
3101 TACTTGTAAT TGTAAATAATC ATTGTTATTA TTATTATACA TATTTTGCTT
3151 TTAAATGGAT AAGGATTTTT AAGGTATATG TAAACTGTAA AACATAAAAT
25 3201 GCAAAATGCC GTAAGAGACA GTAGTAATAA TAATGATTAT TATATTGTTA
3251 TCATTATCTA GCCTGTTTTT TCCTGTTGTG TATTTCTTCC TTAAATGCT
30 3301 TACAGAAATC TGTATCCCCA TTCTTCACCA CCACCCACAC ACATTTCTGC
3351 TTCTTTTCCC ATGCCGGTCA TGCTAACTTT GAAAGCTTCA GCTCTTTCCT
3401 TCCTCAATCC TTCTCCTGGC ACCTCTGATA TGCCTTTTGA AATTCATGTT
35 3451 AAAGAATCCC TAGGCTGCTA TCACATGTGG CATCTTTGTT GAGTACATGA
3501 ATAAATCAAC TGGTGTGTTT TACGAAGGAT GATTATGCTT CATTGTGGGA
40 3551 TTGTATTTTT CTTCTTCTAT CACAGGGAGA AGTGAA

or a degenerate variation thereof.

- 20 -

The sequence for the cDNA encoding human eosinophil eotaxin receptor further comprises the terminator region beginning with nucleotide 4652 and ending with nucleotide 5099 as depicted below (SEQ ID NO:4):

5
4652 TAGGTCAGA TGCAGAAAAT TGCCTAAAGA GGAAGGACCA AGGAGATGAA
4701 GCAAACACAT TAAGCCTTCC AACTCACCT CTAAACAGT CCTTCAAAC
10 4751 TCCAGTGCAA CACTGAAGCT CTTGAAGACA CTGAAATATA CACACAGCAG
4801 TAGCAGTAGA TGCATGTACC CTAAGGTCAT TACCACAGGC CAGGGGCTGG
4851 GCAGCGTACT CATCATCAAC CCTAAAAAGC AGAGCTTTGC TTCTCTCTCT
15 4901 AAAATGAGTT ACCTACATTT TAATGCACCT GAATGTTAGA TAGTTACTAT
4951 ATGCCGCTAC AAAAAGGTAA AACTTTTTAT ATTTTATACA TTAACCTCAG
20 5001 CCAGCTATTG ATATAAATAA AACATTTTCA CACAATACAA TAAGTTAACT
5051 ATTTTATTTT CTAATGTGCC TAGTTCTTTC CCTGCTTAAT GAAAAGCTT

or a degenerate variation thereof.

25
As will be appreciated by one skilled in the art, there is a substantial amount of redundancy in the set of codons which translate specific amino acids. Accordingly, this invention also includes alternative base sequences wherein a codon (or codons) are replaced
30 with another codon such that the amino acid sequence translated by the DNA sequences remains unchanged. For purposes of this specification, a sequence bearing one or more such replaced codons will be defined as a degenerate variation. Also included are mutations (exchanges of individual amino acids) which one skilled in the art would expect to
35 have no effect on functionality, such as valine for leucine, arginine for lysine, and asparagine for glutamine.

- 21 -

The amino acid sequence of CC CKR3 shares some sequence homology with CC CKR1 (Neote, K., et al. (1993) *Cell* **72**, 415-425), CC CKR2B (Charo, I. F., et al. (1994) *Proceeding of the National Academy of Sciences* **91**, 2752-2756), CC CKR4 (Power, C. A., et al. (1995) *Journal of Biological Chemistry* **270**, 19495-19500) and V28 (Raport, C. J., et al. (1995) *Gene* **163**, 295-299). The sequence of this protein, designated CC CKR3, is comparable to that previously reported by Combadiere et al. (Combadiere, C., et al. (1995) *Journal of Biological Chemistry* **270**, 16491-16494) except that it contains a lysine in place of asparagine at position 107. Genomic cloning provided confirmation of the subject sequence, including lysine at position 107. The sequence discrepancy, which results from a substitution of G to T at the third position of the codon for residue 107, could represent a genetic polymorphism. This is highly unlikely, however, because all α - and β -chemokine receptors analyzed to date contain lysine in that position including the recently described basophilic β -chemokine receptor (Power, C. A., et al. (1995) *Journal of Biological Chemistry* **270**, 19495-19500), CC CKR1 (Neote, K., et al. (1993) *Cell* **72**, 415-425), MCP-1R (Charo, I. F., et al. (1994) *Proceeding of the National Academy of Sciences* **91**, 2752-2756), IL-8RA and IL-8RB (Holmes, W. E., et al. (1991) *Science* **253**, 1278-1280; Murphy, P. M., et al. (1991) *Science* **253**, 1280-1283), the three murine β -chemokine receptors (Post, T. W., et al. (1995) *Journal of Immunology* **155**, 5299-5305; Gao, J. L., et al. (1995) *Journal of Biological Chemistry* **270**, 17494-17501) as well as three human chemokine-like receptors (Loetscher, M., et al. (1994) *Journal of Biological Chemistry* **269**, 232-237; Raport, C. J., et al. (1995) *Gene* **163**, 295-299; Combadiere, C., et al. (1995) *DNA and Cell Biology* **14**, 673-680; Federspiel, B., et al. (1993) *Genomics* **16**, 707-712). An unusual feature of CC CKR3 is the cluster of negatively charged amino acids (ETEELFEET) distal to TMIV in the second extracellular loop.

- 22 -

Expression of the Human CC CKR3 in AML14.3D10 Cells

Once a full length cDNA encoding CC CKR3 was isolated and cloned into the expression vector pBJ/NEO the resulting plasmid designated pBJ/NEO/CCCKR3, was transfected into the AML14.3D10
5 line.

The CC CKR3 transfected AML14.3D10 cell line has been placed on restricted deposit with American Type Culture Collection in Rockville, Maryland as ATCC No. CRL-12079, on April 5, 1996.

Stable clones were selected for neomycin resistance, and a
10 number were chosen for further analysis. To demonstrate expression of receptor protein, a western blot was performed using antisera generated against a peptide derived from the predicted C-terminus of CC CKR3. Immunoreactive bands migrating at approximately 45-55 kd are present in primary eosinophils and the 3.16 clone, indicating that CC CKR3 is
15 indeed expressed in these cells. There was no immunoreactive bands present in neutrophils indicating that the antisera was indeed identifying an eosinophil-specific protein. A nonspecific pattern of immuno-reactivity was detected in untransfected AML14.3D10 cells, and furthermore, this pattern was identical in clone 3.49 indicating that this
20 neomycin-resistant clone is a non-expressor of CC CKR3. Of the 27 neomycin resistant clones studied, 19 failed to express CC CKR3. The other 8 did express the receptor as judged both by Western analysis, and by the ability of eotaxin and RANTES to induce Ca^{2+} -fluxes. The non-expressing clones were used as negative controls in subsequent
25 experiments.

Binding to CC CKR3 on Intact AML14/CCCKR3.16 Cells

Because preliminary experiments with three different CC CKR3 expressing clones indicated that they bound ^{125}I -eotaxin,
30 competition studies using this labeled ligand were performed to characterize the binding properties of the receptor. As shown in Table 1, unlabeled human eotaxin competed with an K_d of 0.1 nM. Results with murine eotaxin were essentially identical. Scatchard analysis demonstrated that eotaxin binds with a single affinity and that the

- 23 -

different clones expressed $2-4 \times 10^5$ receptors/cell. The ability to bind eotaxin is due to CC CKR3 since neither immunoreactive negative clones, such as 3.49, nor untransfected cells displayed any specific binding. Clearly, CC CKR3 is a high affinity receptor for eotaxin.

5 Cross-competition studies with the two other β -chemokines known to be eosinophil chemoattractants, RANTES and MCP-3, demonstrated that they too have considerable affinity for CC CKR3, with K_d 's of about 3 nM (See Table 1). In contrast, MCP-1 competed with much lower affinity ($K_d=60$ nM), and MIP-1 α , and MIP-1 β failed to compete at all
10 (See Table 1). Similarly, the α -chemokine IL-8 did not inhibit eotaxin binding.

Competition studies were also carried out against ^{125}I -MCP-3. Again, human and murine eotaxin competed strongly with K_d 's of 0.2 and 0.3 nM (Table 1). RANTES and MCP-3 also demonstrated
15 high affinity with K_d 's of 0.5 and 0.7 nM, values about 4-fold lower than observed against eotaxin. As in the studies with eotaxin, MCP-1 competed weakly ($K_d = 16$ nM), and MIP-1 α , and MIP-1 β failed to compete at all. Thus despite some small quantitative differences the overall ligand selectivity of the receptor is the same whether measured
20 by competition against eotaxin or MCP-3, and the order of potency, eotaxin>MCP-3=RANTES>>MCP-1, is identical.

CC CKR3 is functionally coupled in AML14.3D10 cells

In order to determine whether human CC CKR3 was
25 functionally coupled when expressed in the AML14.3D10 line, intracellular Ca^{2+} levels were measured in response to various β -chemokines. Both 100 nM eotaxin and RANTES induced Ca^{2+} -fluxes in cells expressing the receptor. Surprisingly, 1 μ M of MCP-3 was required to induce a response, and that response was smaller than those
30 observed for eotaxin or RANTES. No response at all was generated by addition of MIP-1 α , MIP-1 β , MCP-1 or IL-8 at concentrations as high as 1 μ M. The responses to eotaxin, RANTES, and MCP-3 are due to the specific expression of CC CKR3 since none of these mediators induced fluxes in untransfected cells or in clone 3.49. While the preliminary

- 24 -

functional characterization by Combadiere et. al. differs greatly from the present invention, they were not able to demonstrate any specific binding to cells putatively expressing the receptor, and such functional data have now been retracted (Combadiere, C., et al. (1995) *Journal of Biological Chemistry* 270, 30235).

Binding properties of primary eosinophils

The selectivity of CC CKR3 for the various β -chemokines mirrors the effectiveness of these ligands as eosinophil chemoattractants suggesting that CC CKR3 is the primary mediator of chemokine induced eosinophil chemotaxis. To provide additional pharmacological evidence, binding studies were conducted on primary eosinophils. When measured by competition against ^{125}I -eotaxin, unlabeled human eotaxin gave an $K_d = 0.1 \text{ nM}$, a value identical to that obtained on cloned CC CKR3 (see Table 1). Scatchard analysis showed a single binding affinity, and 4×10^5 sites/cell. The number of binding sites varied by less than 2-fold for the 3 donors used in the studies. The affinities for RANTES and MCP-3 were also identical to those measured on CC CKR3, and as with CC CKR3, neither MIP-1 α , or MIP-1 β , showed any ability to compete with radiolabeled eotaxin (see Table 1). Similarly, the K_d 's obtained by competition against ^{125}I -MCP-3 on eosinophils are effectively indistinguishable to those measured against cloned CC CKR3 (see Table 1). All of the observations and measurements, taken together with the Western blot showing expression of CC CKR3, verify that CC CKR3 is the eosinophil eotaxin receptor, and appears to be largely responsible for mediating the effects of most β -chemokines on eosinophils.

Stably expressed in the eosinophilic line AML14.3D10, CC CKR3 binds eotaxin, RANTES and MCP-3, with high affinity, with a rank order of potency of eotaxin>RANTES=MCP-3. MCP-1 binds with much lower affinity, while MIP-1 α and MIP-1 β fail to bind at all. The selectivity of CC CKR3 mirrors most of the binding activity of primary eosinophils. In fact, when measured by competition against ^{125}I -eotaxin, the binding affinities on eosinophils for all of these β -

- 25 -

chemokines are indistinguishable from those obtained with cloned CC
CKR3. Moreover, CC CKR3 was cloned from eosinophils, and as
shown by Western blotting is heavily expressed in these cells. The
abilities of the different chemokines to activate CC CKR3 are consistent
5 with the binding data as eotaxin, RANTES, and to a lesser extent MCP-
3 all stimulate Ca^{2+} fluxes in clones which express the receptor, while
MCP-1, MIP-1 α and MIP-1 β do not, even at concentrations as high as
1 μM . Thus, based on its properties, and expression, CC CKR3, is the
eosinophil eotaxin receptor.

10

- 26 -

TABLE 1

Binding affinities of various chemokines comparing CC CKR3
expressed in AML14.3D10 with primary eosinophils

5		<u>K_d (nM)</u>	
	<u>competitor</u>	<u>CC CKR3</u>	<u>eosinophils</u>
		¹²⁵ I-human eotaxin	
10	human-eotaxin	0.1±0.04 (4)	0.1±0.03 (3)
	murine-eotaxin	0.1±0.04 (3)	0.1±0.01 (2)
	MCP-3	2.7±1.7 (5)	3.0±0.2 (2)
	RANTES	3.1±0.6 (5)	2.6±0.3 (2)
	MCP-1	60±9 (3)	41±2 (2)
15	MIP-1α	N.B. (4)	N.B. (2)
	MIP-1β	N.B. (4)	N.B. (2)
		¹²⁵ I-MCP-3	
	human-eotaxin	0.2±0.1 (4)	0.2±0.1 (2)
20	murine-eotaxin	0.3±0.1 (2)	0.2±0.1 (3)
	MCP-3	0.7±0.4 (4)	1.1±0.6 (10)
	RANTES	0.5±0.3 (4)	0.9±0.4 (8)
	MCP-1	16±2 (3)	61±13 (2)
	MIP-1α	N.B. (4)	see text
25	MIP-1β	N.B. (4)	N.B. (2)

Competition binding experiments were carried out against
the indicated iodinated ligand as follows and as described herein.

Equilibrium binding of β-chemokines to AML14.3D10 cells expressing
CC CKR3 and to primary eosinophils was examined with increasing
concentrations of unlabelled human eotaxin, murine eotaxin, RANTES,
MCP-3, or MCP-1 to compete against fixed concentrations of either
¹²⁵I-human eotaxin, or ¹²⁵I-MCP-3. Also the competition with 100 nM
concentrations of MIP-1α, and MIP-1β was examined. The experiments

- 27 -

were carried out either with AML14.3D10 cells expressing CC CKR3, or with eosinophils. All values are the averages of triplicate determinations. Typically, 4000-6000 cpm of iodinated ligand was bound in the absence of competitor with S/N ratios exceeding 15.

- 5 Human and murine eotaxin are the human and murine chemokines, respectively. "N.B." means that no competition was observed. All results are the averages of the number of experiments shown in parenthesis.

- 10 Various changes and modifications may be made in the products and processes of the present invention without departing from the spirit and scope thereof. The various embodiments and the examples which have been set forth herein are given for the purpose of illustrating the present invention and shall not be construed as being limitations on the scope or spirit of the instant invention.

15

EXAMPLE 1

mRNA Isolation and cDNA Cloning

- 20 Total RNA was isolated from purified eosinophils with TRIzol reagent (BRL) and used in a RT/PCR reaction (Daugherty, B. L., et al. (1991) *Nucleic Acids Research* **19**, 2471-2476) using oligonucleotide primers designed from the human CC CKR1 and MCP-1RB cDNA sequences (Neote, K., et al. (1993) *Cell* **72**, 415-425; Charo, I. F., et al. (1994) *Proceeding of the National Academy of Sciences* **91**, 2752-2756). The primers used for PCR corresponded to a consensus sequence encoded in transmembrane domains (TM) II and VII:

5'-PCR primer (TMII) (SEQ ID NO:5):

5'-AACCTGGCCAT(C,T)TCTGA(C,T)CTGC-3'

- 30 3'-RT/PCR primer (TMVII) (SEQ ID NO:6):

5'-GAAC(C,T)TCTC(C,A)CCAACGAAGGC.

The resultant PCR product of ~700 bp was subcloned into plasmid pNoTA (Five Prime, Three Prime, Inc) and sequenced using Sequenase (USB). The remaining 5' and 3' sequence encoding CC

- 28 -

CKR3 was cloned by rapid amplification of cDNA ends (RACE) using both the 5'-RACE and 3'-RACE kits (Clontech) with the following primer sequences:

(5'-RACE) (SEQ ID NO:7):

5 5'-TCTCGCTGTACAAGCCTGTGTG-3';

(3'-RACE) (SEQ ID NO:8):

5'-CCTTCTCTCTTCCTATCAATCC-3'.

The resultant PCR products (5'-RACE, ~450 bp; 3'-RACE, ~700 bp) were subcloned into pCRII (Invitrogen) and sequenced. Upon
10 identification of the 5'-end of the cDNA containing the initiator ATG codon and the 3'-end containing the termination codon TAG, a new set of PCR primers were designed to reamplify the entire coding region from eosinophil total RNA for expression of CC CKR3. The primer sequences used for RT/PCR were:

15 5'-PCR primer (SEQ ID NO:9):

5'-ATATATTAAGCTTCCACCATGACAACCTCACTAGATACAG-3';

3'-RT/PCR primer (SEQ ID NO:10):

5'-ATATATTCTAGAGCGGCCGCTAAAACACAATAGAGAGTTCC-3'.

20 The resultant PCR product of 1105 bp was digested with HindIII and NotI and subcloned into plasmid pBJ/NEO to yield pBJ/NEO/CCCKR3. The plasmid pBJ/NEO was prepared essentially as follows. Plasmid pD5/Igh/Neo (Daugherty, B.L., et al. (1991) *Nucleic Acids Research* 19, 2471-2476) was digested with the restriction
25 enzyme *Sal*I, filled in with *E. coli* DNA polymerase I Klenow fragment to create a blunt end and subsequently digested with the restriction enzyme *Not*I. The CMVIE intron A fragment from plasmid p89-11 was digested with *Cl*aI, filled in to create a blunt end and subsequently digested with *Hind*III. These fragments were used in a three-way
30 ligation with a *Hind*III and *Not*I fragment of the human C5a receptor cDNA. The C5a receptor fragment was excised with *Hind*III and *Not*I and replaced with the eotaxin receptor cDNA of 1105 bp obtained by RT/PCR with oligonucleotides SEQ ID NO:9 and SEQ ID NO:10 after digestion with *Hind*III and *Not*I. Several clones were sequenced and one

- 29 -

clone comprising the consensus sequence was chosen for expression of CC CKR3 in heterologous cells.

EXAMPLE 2

5

Transfection into AML14.3D10 Human Eosinophilic Cell Line

AML14.3D10 cells (Paul, C. C., et al. (1995) *Blood* 86, 3737-3744) were cultured in RPMI-1640, 10% FBS, 1 mM sodium pyruvate, 0.5 μ M β -mercaptoethanol and 2 mM L-glutamine (complete medium). Cells were harvested at a density of 0.3×10^6 /mL, washed
10 once in PBS, resuspended in RPMI at 10^7 /mL, and 25 μ g of plasmid was added. Electroporation was carried out at 300 V, 960 μ F using a Gene Pulser (BioRad). Following electroporation, cells were chilled at 0°C for 10 min and then plated in complete medium at 10^6 /T75 flask
15 and cultured at 37°C , 5% CO_2 . After 16-24 hr, cells were pelleted and resuspended in complete medium containing 2 mg/mL Geneticin (GIBCO). Cells were maintained in selection medium for 8-10 days until individual surviving clusters appeared. Individual cells were then transferred to 96-well plates and expanded. AML14/CCCKR3 sublines
20 were assayed for the ability to generate a Ca^{2+} flux in response to either RANTES or eotaxin. Positive sublines were then probed by western blotting with an antibody raised against the predicted C-terminus of CC CKR3. Cell lines positive in both sets of assays were then characterized for their ability to bind to a variety of CC
25 chemokines, including eotaxin, RANTES, MCP-3, MIP-1 α , MIP-1 β and MIP-1.

- 30 -

EXAMPLE 3Purification of Eosinophils

Primary eosinophils were isolated from granulophoresis
5 preparations obtained from allergic and asthmatic donors (Bach, M. K.,
et al. (1990) *Journal of Immunological Methods* **130**, 277-281). The
leukocytes were mixed with equal volumes of HBSS and layered over
LSM (Organon Teknika) as described (Rollins, T. E., et al. (1988)
Journal of Biological Chemistry **263**, 520-526). After lysis of
10 erythrocytes with NH₄Cl, the granulocytes were subsequently treated
with anti-CD16 microbeads followed by MACS separation (Miltenyl
Biotech) (Hansel, T. T., et al. (1991) *Journal of Immunological Methods*
145, 105-110). Typically the eosinophil preparations were >99% pure
as determined using the LeukoStat staining kit (Fisher).

15

EXAMPLE 4Generation of α -CC CKR3 antisera and immunoblotting

Polyclonal rabbit antisera was generated to CC CKR3 using
20 the C-terminal decapeptide sequence TAEPELSIVF. Peptide synthesis,
coupling to thyroglobulin and production of antisera was performed
(Miller, D. K., et al. (1993) *Journal of Biological Chemistry* **268**,
18062-18069). Whole cells were boiled and sonicated in Laemli sample
buffer (Laemmli, U. K. (1970) *Nature* **227**, 680-685), electrophoresed
25 on 4-20% SDS gels (Novex), transferred to polyvinylidene difluoride
membranes (BioRad), and blocked with 5% nonfat dry milk in TBST
(20 mM Tris, 200 mM NaCl, 0.1% Tween-20) for 16 hr at 4°C. The
membrane was incubated with antisera at 1:1000 in TBST for 1 hr at
room temperature, washed, and subsequently incubated with goat anti-
30 rabbit HRP (Zymed) at 1:4000 in TBST for 30 min also at room
temperature. After washing, the membrane was treated with ECL
western blotting reagents (Amersham) for 1 min, covered in plastic
wrap and exposed to film for 2 min.

- 31 -

EXAMPLE 5Chemokine binding assays

Recombinant MCP-3, MCP-1, RANTES, murine and
5 human eotaxin were obtained from Peprotech (Princeton, NJ). ^{125}I -
MCP-3 and ^{125}I -MIP-1 α were obtained from New England Nuclear
(Boston, MA), and ^{125}I -human-eotaxin was obtained from Amersham.
Binding of ^{125}I -labeled ligands (typically a total of 2×10^4 cpm) in the
presence of varying concentrations of unlabeled ligands to intact cells
10 (typically 1.5×10^4 , 10^5 , or 10^6 for experiments with labeled eotaxin,
MCP-3, or MIP-1 α , respectively) were performed at 32°C (Van Riper,
G., et al. (1993) *Journal of Experimental Medicine* 177, 851-856).

EXAMPLE 6

15 Ligand-induced Ca^{2+} fluxes

Human CC CKR3 expressing AML14 clones or purified
eosinophils were incubated with $1.25 \mu\text{g/ml}$ Indo-I (Molecular Probes,
Eugene, OR) in RPMI 1640, 10 mM HEPES, 5% FBS, for 60 min at
20 37°C (Van Riper, G., et al. (1993) *Journal of Experimental Medicine*
177, 851-856). Loaded cells were washed and incubated at 37°C
before the addition of ligands. Calcium fluxes were performed on a
FACS analyzer (Becton Dickinson & Co., Mountain View, CA) with an
excitation wavelength of 365 nm and dual emission wavelength of 405
25 and 488 nm.

EXAMPLE 7CC CKR3 Binding Assay

30 Assay buffer (50 mM Hepes, pH 7.2 w/ 0.5% BSA, 5 mM
MgCl₂, 1 mM CaCl₂, 100 μM PMSF and 10 $\mu\text{g/ml}$ phosphoramidon,
leupeptin, aprotinin and chymostatin), test compound (or equivalent
volume of solvent), 20 pM ^{125}I -human eotaxin (2000 Ci/mmol), 25 ng
unlabeled human eotaxin (non-specific binding wells only), and

- 32 -

AML14.3D10 cells expressing eotaxin receptor cells, or eosinophils, are added sequentially in 96-well, round-bottom, polystyrene plates to a final volume of 250 μ L. Assay plates are then mixed and incubated for 60 minutes at 31°C. After incubation, assay plates are harvested onto
5 Packard 96-well GF/C Unifilter plates treated with 0.33% polyethylenimine (PEI) using Packard Filtermate 196 cell harvester. Wells and filters are washed with 200 μ L 50 mM Hepes, pH 7.2 with 0.5M NaCl and 0.02% NaN₃. After filtration, GF/C plates are dried and sealed. 25 μ L Packard Microscint-O scintillant are then added to
10 each well and counted for 2 minutes on Packard Topcount (liquid 125I setting).

EXAMPLE 8

15 Phosphoinositide 3-kinase (PI-3K) Assay

AML14.3D10 expressing eotaxin receptor (CCCKR3) cells are incubated with test compound and stimulated with eotaxin, RANTES, or MCP-3, pelleted and lysed in 1 mL lysis buffer (1% Nonidet P-40, 100 mM NaCl, 20 mM Tris, pH 7.4, 10 mM iodoacetamide, 46 mM b-
20 glycerophosphate, 10 mM NaF, 1 mM PMSF, 1 μ g/mL leupeptin, 1 μ g/mL chymostatin, 1 μ g/mL antipain, 1 μ g/mL pepstatin A, and 1 mM sodium orthovanadate). Lysates are then pre-cleared for 1 hr with uncoupled protein A Affi-Gel beads. Immunoprecipitation is then performed with p85 polyclonal antiserum (1 μ L/mL lysate; Upstate
25 Biologics, New York, NY), coupled to protein A Affi-Gel beads (Bio-Rad) at 4°C for 2 hr. Immunoprecipitates are washed and subjected to in vitro lipid kinase assays by using a lipid mixture, 100 μ L 0.1 mg/ml PtdIns and 0.1 mg/ml phosphatidylserine dispersed by sonication into solution in 20 mM HEPES, pH 7.0, and 1 mM EDTA. The reaction is
30 initiated by the addition of 100 mM ATP and 20 μ Ci [γ -³²P]ATP (3000 Ci/mmol) in 20 μ L kinase buffer. The reaction is then terminated after 15 min and the phosphoinositide lipids are separated by thin layer chromatography (TLC) and visualized by exposure to iodine vapor autoradiography.

- 33 -

EXAMPLE 9Chemotaxis Assay

AML14.3D10 expressing eotaxin receptor cells are isolated by centrifugation (van Riper, G., et al. (1994) *J. Immunol.* **152**, 4055-4061) for 15 min at 150 X g, washed and resuspended at 10^7 cells/ml in HBSS (pH 7.4) containing 1 mM CaCl_2 and 1 mM MgCl_2 (chemotaxis buffer). The chemotaxis experiments is then performed in Transwell dishes (6.5 mm, Costar, Cambridge, MA). The lower chamber contains 0.6 ml of chemotaxis buffer and is separated from the upper chamber containing 10^6 cells by a 5-mm pore Nucleopore polycarbonate membrane (Nucleopore Corporation, Pleasanton, CA). After a 15 min preincubation at 37°C , test compound and eotaxin, RANTES, or MCP-3 are added to the lower chamber to a final concentration of 300 nM. After 2 hrs at 37°C , the upper chamber inserts are removed, and the cells that migrate to the lower chamber are enumerated by a Coulter Counter (Coulter Electronics, Hialeah, FL).

EXAMPLE 10Ligand-Dependent Inositol Phosphate Release Assay

AML14.3D10 expressing eotaxin receptor cells are labeled with [^3H] inositol (10 $\mu\text{Ci/ml}$) for 24 hrs as described (Wu, D., et al. (1993) *Science* **261**, 101-103). Test compound and various concentrations of eotaxin, MCP-3, or RANTES are then added to the cells for 30 min. The cells are lysed in 10% perchloric acid, neutralized in 2 N KOH and centrifuged. The supernatant is transferred to columns containing 0.5 ml AG1-X8 anion exchange resin, washed with 6 ml borax buffer and eluted with 0.3 ml formic acid (0.1 M). The eluted samples are mixed with scintillation cocktail and counted.

- 34 -

EXAMPLE 11Acidification Rate Assay

5 AML14.3D10 expressing eotaxin receptor cells are subject to serum starvation for 16 hrs. The cells are then mixed at a 3:1 (v/v) ratio with low melting temperature agarose. A 10 ul drop of the cell/agarose mixture is pipetted into a sterile Capsule Cup (Molecular Devices) at a cell density of approximately 200,000 cells/cup. The cell/agarose drop forms a gel after about 5 min, and is assembled into
10 the cup between two 3 um porosity polycarbonate membranes with running medium. The assembled capsule cups is placed into the sensor chambers and then placed on the Cytosensor Microphysiometer (Molecular Devices) containing 1 ml of running medium. The chambers are allowed to equilibrate for 1 hr at 37°C with a flow rate of
15 100 ul/min. The experiment is initiated with an 8 min exposure of eotaxin, RANTES, MCP-3 and test compound at various concentrations and the acidification rate over baseline will be measured in the medium (McConnell, H.M., et al. (1992) *Science* 257, 1906-1912) until the cells return to the unstimulated level.

20

EXAMPLE 12Actin Polymerization Assay

25 AML14.3D10 expressing eotaxin receptor cells are diluted in APA buffer (HBSS; 25mM Hepes; 0.2% BSA, pH7.2) at a concentration of 4×10^6 /ml. One ul of test compound and eotaxin, RANTES, or MCP-3 added into a 96-well plate and incubated at 37°C. 100 ml of cells are added to the plate and incubated for 20 sec to which 100 ml of APA cocktail (2 mls 8% formaldehyde; 460uLs 0.33uM Rhodamine-phalloidin; 1.85 mg 200ug/ml lysolecithin; 7.25 mls HBSS) is added.
30 Plates are then centrifuged at 2000 RPM for 5 min, cleared and then 100 ul of HBSS is added to all wells which are read in a Fluoroskan II fluorometer.

- 35 -

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, procedures other than the particular experimental procedures as set forth herein above may be applicable as a consequence of degeneracy and variations in the sequences of the proteins and DNA of the invention indicated above. Likewise, the characterization data observed may vary slightly according to and depending upon the particular assay or characterization method employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

- 36 -

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: DAUGHERTY, BRUCE L.
DEMARTINO, JULIE A.
SICILIANO, SALVATORE J.
SPRINGER, MARTIN S.
- (ii) TITLE OF THE INVENTION: EOSINOPHIL EOTAXIN RECEPTOR
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Merck & Co., Inc.
 - (B) STREET: P.O. Box 2000, 126 E. Lincoln Ave.
 - (C) CITY: Rahway
 - (D) STATE: NJ
 - (E) COUNTRY: USA
 - (F) ZIP: 07065-0900
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: 60/016,158
 - (B) FILING DATE: 26-APR-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Eric Thies, J.
 - (B) REGISTRATION NUMBER: 35,382
 - (C) REFERENCE/DOCKET NUMBER: 19634Y
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 908-594-3904
 - (B) TELEFAX: 908-594-4720
 - (C) TELEX:

- 37 -

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 355 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
 1           5           10           15
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
 20           25           30
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
 35           40           45
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
 50           55           60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
 65           70           75           80
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
 85           90           95
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
100           105           110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
115           120           125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
130           135           140
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
145           150           155           160
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
165           170           175
Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
180           185           190
Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
195           200           205
Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
210           215           220
Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu
225           230           235           240
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
245           250           255
Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp
260           265           270
Cys Glu Arg Ser Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val
275           280           285
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
290           295           300
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu
305           310           315           320
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
325           330           335
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
340           345           350

```

- 38 -

Ile Val Phe
355

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1065 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGACAACCT CACTAGATAC AGTTGAGACC TTTGGTACCA CATCCTACTA TGATGACGTG
60
GGCCTGCTCT GTGAAAAGC TGATACCAGA GCACTGATGG CCCAGTTTGT GCCCCCGCTG
120
TACTCCCTGG TGTTCACGTG GGGCCTCTTG GGCAATGTGG TGGTGGTGAT GATCCTCATA
180
AAATACAGGA GGCTCCGAAT TATGACCAAC ATCTACCTGC TCAACCTGGC CATTTCCGGAC
240
CTGCTCTTCC TCGTCACCCT TCCATTCTGG ATCCACTATG TCAGGGGGCA TAACTGGGTT
300
TTTGGCCATG GCATGTGTAA GTCCTCTCA GGGTTTTATC ACACAGGCTT GTACAGCGAG
360
ATCTTTTTCA TAATCCTGCT GACAATCGAC AGGTACCTGG CCATTGTCCA TGCTGTGTTT
420
GCCCTTCGAG CCCGGACTGT CACTTTTGGT GTCATCACCA GCATCGTCAC CTGGGGCCTG
480
GCAGTGCTAG CAGCTCTTCC TGAATTTATC TTCTATGAGA CTGAAGAGTT GTTTGAAGAG
540
ACTCTTTGCA GTGCTCTTTA CCCAGAGGAT ACAGTATATA GCTGGAGGCA TTTCCACACT
600
CTGAGAATGA CCATCTTCTG TCTCGTTCTC CCTCTGCTCG TTATGGCCAT CTGCTACACA
660
GGAATCATCA AAACGCTGCT GAGGTGCCCC AGTAAAAAAA AGTACAAGGC CATCCGGCTC
720
ATTTTTGTCA TCATGGCGGT GTTTTTTATT TTCTGGACAC CCTACAATGT GGCTATCCTT
780
CTCTCTTCTT ATCAATCCAT CTTATTTGGA AATGACTGTG AGCGGAGCAA GCATCTGGAC
840
CTGGTCATGC TGGTGACAGA GGTGATCGCC TACTCCCACT GCTGCATGAA CCCGGTGATC
900
TACGCCTTTG TTGGAGAGAG GTTCCGGAAG TACCTGCGCC ACTTCTTCCA CAGGCACTTG
960
CTCATGCACC TGGGCAGATA CATCCCATTC CTTCTTAGTG AGAAGCTGGA AAGAACCAGC
1020
TCTGTCTCTC CATCCACAGC AGAGCCGGAA CTCTCTATTG TGTTT
1065

- 39 -

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3586 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
GGATCCCTAC CTTCCCCATC AGAGCTAGGG GGCATGGAGC GCTCTCTGCT AAGATGGGGA
60
CCCCCAAGGA ATGTCTCCCT GTGGGGCACT TCCTTACCAG ATGGGATGGC CAGTGC GGTT
120
AAGTTGGTGG TCAGGCAGAA AAAAAAGATC TAGTTTGTAC TCTTGAGAGT TCCTCGGTTT
180
GTTTCATGGCA TGGGCAGGGA GTCAAGGAGC AGCAGCCTTG CCTCAGTGCC TACCAGTGCA
240
GGAAAAGGTG CATAGCCTGG GCCAGGGCCA GGGCCCTGGT GGAGGCGTAG TGGTAACAGA
300
GAGGGCTCTC CATTCAGCC CAAGGAAGAC TAAGAATGAA TACCTCATGA GTATATTAGC
360
TACAAACCAC CACAGCAGGT TCCAGAAAAA GGCTCAGCGT TGGAAACCAGG TCACCCCCAC
420
TCAGCAGACA CCAGTCATAT AAATCAAGGA CCAACAGGAG ACAGGAACAC CCCCTTCCCA
480
CTCTGCCCCA TGTCTCAAGT TGTAGTGGCC CTTCTCCAG ATCTCTGCCA CCATCTTAGA
540
AAGGAACACT GAAAGAAGAA ACTGAAATTA TAAGCTGACA GCATAAAGAG GATGAGTAAA
600
ACCTAAAATC ATTGTTTACA TGAATGAATC AAGAGAAGTT TAAACCACTT TGGACTAAAA
660
TGTGTGAATC CTTTTTCCTG CTATCCAGCA GATGAGAAGC TGGTAACAGA GACCACAATA
720
GTTTGGAGAC TAAAGAATCA TTGCACATTT CACTGCTGAG TTGTATTGTG AGTAATTTTA
780
GTTGACCTCA CTTTGTAAT CTTGCACACG GGGCAATCCA ATATCTGCAC AAGAGATATG
840
TTAACCAGTG GTAAATGCTG CATGAGGAGA TTGGGTGATT TTTACTTTCG TTTTGTGCT
900
CTTCTTTCTT ATTGTTCTTA CTTATTTACG ATTACCCTAT CGTTTTCCCA AAATGTAAAA
960
GGCCATTTTG AAAGCCTAAT TCAAACCTCT TCACTATTTT GTATCTAAGT ATTCACCTTG
1020
ATTGAGACTG GGTAGACAGG TGAAAACCAT ATCAGGTTTT TAATTTTTTA ATTTTAAAT
1080
ATTTATTAT TTTTATTTT TTTGAGATGG AGTCTGGCTG TCGCCCAGGC TGGAGTGCAG
1140
CGGCGTGATC ACAGTTCCT GCAGCCTCAA CCTTCTAGGC TCAAGGGATT CTCCACCTC
1200
AGCCCCCAA GTAGTTGGGA CCACACGTAT GCGCCACCAT GCCTGGCTAA TTTCTTATTT
1260
TTTTGTAGAG ATAGGATCTC ACTATATTGT CCAGGCTGGT CTTGAATCC TGGGCTCAGG
1320
```

- 40 -

TGAGCCTCCC ACCTGGGCCT CCCAAAGTAC TGGGATTACA GGCATGAGCC AAGGTCCCCCT
1380
GCCCATATGA GATTTTCTGT CTCTGATCCC ATGCAGCTAG TAATCAAGGA CTTGGCTGCT
1440
GACTCTGGAG GACCTGCATG CTTTCTTGAG CTGTGAACTT CAGTGCTAAA AGCTCATAGG
1500
CAGCCCTGAA ACCCAAACCA AAAGGTTCTA TGGTTTATCA TCCTGATCAT GTTGATTTTA
1560
TAGAAATAAC ACATGAATTA AAGACACTAC CCTCAAACCTG AGCAAACTT AAGTAATTTT
1620
TTTAAAGTTT GACCTGTTTT TAAATCACTC TTGGAGAAAA AGGAAAATAA ATACAAATAA
1680
TTAACGGTGA ATACAGGCTA CTATACCTTT GTTCTCCAGA ATTAGCAGTT CTGTTCTTTT
1740
CTTGCTTTAG ATGCTGAAGT GCAGAAGGAC ACTCTGTGAT TGTACGTGTG TAACTGACAA
1800
AATGTGTATT TTTTTTCTCA GCTGCTATGG ATTGGATTAT GCTATTATGA ATAAGAATGC
1860
TGATGGGAGC ACACACAAAC CATTTGTTCC TCAGTCCATT TTCCTCCTCA AAAGCCTGGA
1920
ATGTGCCATT GATCAGTGGG AGATGTACCT GGACAGACCC ATGAAAAGAG ATCAACAAGT
1980
TCCACCCAAG GGACCCTATT TTTCTTAATT TCATTTGAAA TGGCTTCTAA TTGTCTTCT
2040
TTCATTCTCG CTTCTACCA GTTTTACAGC TTTTCTGGT TTCAAATGTG AACTCACATA
2100
CACTCTCATT TTTCTCATC ACAACCCCAA GTGACCCAAT GGTCTCACT TTCGATATAA
2160
GTAAAGGAGG CTCTGCATTA AGGGCTTGTC CAAGGCACGC AGCTGAGAGG CGCTAGGACT
2220
GGCTCCATTT CCATCTCTAT TCTCACTGAC TTTGACTACC CAGAACCCCA ACATGTGGGG
2280
CCTCAGTATT CGATCAATTA TTCTATTAAG AAGCAAAAAC AATTCCCCGC ATTGGCCCCA
2340
GTTATTAAGC ATTTCTCAGA TTTACCTTGA GAAATGCCCA TCGGCCTGTA TATTCACATC
2400
TTCACCCTTG TCCCTTCCTC CTAGAAAGGA GAAAGTCAGT TGGATGCCCT CTGAGGAACT
2460
AGTGCATGGC TTAAGTGTCC TTCCATGACT CCTGCCTTAT CTGTTTTCTA TTTTCTCCT
2520
TTTCCACCGA AGTCTATAAT CTCAAGAAAA GCAGGCACTG GCCTTAGGGC TCCTGGCCTA
2580
AGAAATATCA AGTCCAGTGA GAAATCCCAT TGAAGTACCC CTCCTGCTTA CCCCTTTGTG
2640
ATGGAGAAGC TCCCAGGGGT TTGCTTTTTG CATGTTACCA GGCCTAACTC AGCATCACCA
2700
GGGGCAAGAA AAGGAAAGTA ACCTAAACTA ATGCTGCTTA TAATTGTAAT TATTGTAATA
2760
GTTAATTACT GTGATTGTAC ATGTGTAACA GACAAAATGT GTATTTTTTT CACAGCTGCT
2820
GTGGATTGGA TTATGCCATT TGGAAATAAGA ATGCTGTTAA GAGCACACAA GCCAGGTTCC
2880
TCAAGTCCGT AGCAAATTTT TCAAAAAGTTA AATTTAAAAA TCACTACATT TGAATCTAGT
2940
GACAGGAGAA ATGGACATGG ATAGAGACTA AAGATCTAGC CCAAATTTTA TATTTACTTG
3000

- 41 -

TTAGAGGATT TTGAACAAAT TACTAAATTT CTTCAGGTT CAATTTCCCC ATTA ACTATA
 3060
 ATGAATGTCT CATCATTATG GGGCCCTGGA GAAGCATAAT TACTTGTAAT TGTAATAATC
 3120
 ATTGTTATTA TTATTATACA TATTTTGCTT TTAAATGGAT AAGGATTTTT AAGGTATATG
 3180
 TAAACTGTAA AACATAAAAT GCAAAATGCC GTAAGAGACA GTAGTAATAA TAATGATTAT
 3240
 TATATTGTTA TCATTATCTA GCCTGTTTTT TCCTGTTGTG TATTTCTTCC TTAAATGCT
 3300
 TACAGAAATC TGTATCCCCA TTCTTCACCA CCACCCACACA ACATTTCTGC TTCTTTTCCC
 3360
 ATGCCGGTCA TGCTAACTTT GAAAGCTTCA GCTCTTTCCT TCCTCAATCC TTCTCTGGC
 3420
 ACCTCTGATA TGCCTTTTGA AATTCATGTT AAAGAATCCC TAGGCTGCTA TCACATGTGG
 3480
 CATCTTTGTT GAGTACATGA ATAAATCAAC TGGTGTGTTT TACGAAGGAT GATTATGCTT
 3540
 CATGTGGGA TTGTATTTTT CTCTTCTAT CACAGGGAGA AGTGAA
 3586

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 448 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TAGGTCAGAT GCAGAAAATT GCCTAAAGAG GAAGGACCAA GGAGATGAAG CAAACACATT
 60
 AAGCCTTCCA CACTCACCTC TAAAACAGTC CTTCAAACCT CCAGTGCAAC ACTGAAGCTC
 120
 TTGAAGACAC TGAAATATAC ACACAGCAGT AGCAGTAGAT GCATGTACCC TAAGGTCATT
 180
 ACCACAGGCC AGGGGCTGGG CAGCGTACTC ATCATCAACC CTAAAAGCA GAGCTTTGCT
 240
 TCTCTCTCTA AAATGAGTTA CCTACATTTT AATGCACCTG AATGTTAGAT AGTTACTATA
 300
 TGCCGCTACA AAAAGGTAAA ACTTTTTATA TTTTATACAT TAACTTCAGC CAGCTATTGA
 360
 TATAAATAAA ACATTTTCAC ACAATACAAT AAGTTAACTA TTTTATTTTC TAATGTGCCT
 420
 AGTTCTTTCC CTGCTTAATG AAAAGCTT
 448

- 42 -

WHAT IS CLAIMED IS:

1. An eosinophil eotaxin receptor, free from
receptor-associated proteins.
2. The eosinophil eotaxin receptor of Claim 1 which is
human.
3. An isolated eosinophil eotaxin receptor.
4. The eosinophil eotaxin receptor of Claim 3 which is
human.
5. The receptor of Claim 2 which comprises a full
length receptor or which comprises the amino acid sequence (SEQ ID
NO:1).
6. The receptor of Claim 4 which comprises a full
length receptor or which comprises the amino acid sequence (SEQ ID
NO:1).
8. A functional equivalent of the eosinophil eotaxin
receptor of Claim 1.
9. A nucleic acid which encodes an eosinophil eotaxin
receptor or a functional equivalent, said nucleic acid being free
from associated nucleic acids.
10. A nucleic acid according to Claim 9 which encodes a
human eosinophil eotaxin receptor, or a functional equivalent.

- 43 -

11. The nucleic acid of Claim 10 which is a DNA.
12. The nucleic acid of Claim 11 which comprises the nucleotide sequence (SEQ ID NO:2).
- 5 13. The nucleic acid of Claim 12 which further comprises the nucleotide sequence (SEQ ID NO:3).
- 10 14. The nucleic acid of Claim 13 which further comprises the nucleotide sequence (SEQ ID NO:4).
- 15 15. A vector comprising a nucleic acid which encodes an eosinophil eotaxin receptor receptor, or a functional equivalent.
16. A vector according to Claim 15 which is selected from the group consisting of: plasmids, and modified viruses, yeast artificial chromosomes, bacteriophages and cosmids or transposable elements
- 20 17. A vector according to Claim 16 wherein the nucleic acid encodes human eosinophil eotaxin receptor receptor or a functional equivalent.
- 25 18. A host cell comprising a vector according to Claim 17.
19. The host cell of Claim 18 wherein the nucleic acid encodes human eosinophil eotaxin receptor receptor, or a functional equivalent.
- 30 20. The host cell of Claim 19 which is from the AML14.3D10 cell line.

- 44 -

21. A nucleic acid encoding an eosinophil eotaxin receptor clone that belongs to the β -chemokine receptor family and that hybridizes with a nucleotide which a human eosinophil eotaxin receptor under reduced stringency of hybridization.

5

22. A method to determine the presence of a compound which binds to an eosinophil eotaxin receptor comprising:

- (a) introducing a nucleic acid which encodes an eosinophil eotaxin receptor into a cell under conditions so that
10 eosinophil eotaxin receptor is expressed;
(b) introducing a detector molecule or a nucleic acid encoding a detector molecule into the cell, wherein the detector molecule is directly or indirectly responsive to a eosinophil eotaxin-ligand binding event;
15 (c) contacting the cell with a compound suspected of binding to the eosinophil eotaxin receptor; and
(d) determining whether the compound binds to the eosinophil eotaxin receptor by monitoring the detector molecule.

20 23. The method of Claim 22 wherein the eosinophil eotaxin receptor is human.

24. The method of Claim 22 wherein the nucleic acid which encodes an eosinophil eotaxin receptor comprises the nucleotide
25 sequence (SEQ ID NO:2).

25. The method of Claim 22 wherein the result of step (d) is compared to that obtained using a known ligand of the eosinophil eotaxin receptor.

30

26. The method of Claim 25 wherein the known ligand of the eosinophil eotaxin receptor is eotaxin.

- 45 -

27. The method of Claim 25 wherein the known ligand of the eosinophil eotaxin receptor is RANTES.

5 28. The method of Claim 25 wherein the known ligand of the eosinophil eotaxin receptor is MCP-3.

29. The method of Claim 22 wherein the eosinophil eotaxin receptor is expressed in a host cell which does not naturally express the human eosinophil eotaxin receptor

10

30. The method of Claim 29 wherein the host cell is from the AML14.3D10 cell line.

15 31. A ligand identified by the method of Claim 22.

32. A ligand identified by the method of Claim 23.

33. A ligand identified by the method of Claim 24.

20 34. A ligand identified by the method of Claim 25.

35. A ligand identified by the method of Claim 30.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06568

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/705, 14/715; C12N 15/12

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/7.2, 7.21, 69.1, 70.1, 71.1, 71.2, 172.3, 325, 252.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PONATH et al. Cloning of the Human Eosinophil Chemoattractant, Eotaxin. J. Clin. Invest. February 1996, Vol. 97, No. 3, pages 604-612, especially pages 606-607.	1-21
X,P	PONATH et al. Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils. J. Exp. Med. June 1996, Vol. 183, pages 2437-2448, especially pages 2439-2441.	1-21
X,P	DAUGHERTY et al. Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor. J. Exp. Med. May 1996, Vol. 183, pages 2349-2354, especially pages 2350-2351.	1-21

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 AUGUST 1997

Date of mailing of the international search report

11 SEP 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06568

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	VAN DAMME et al. Structural and Functional Identification of Two Human, Tumor-derived Monocyte Chemotactic Proteins (MCP-2 and MCP-3) Belonging to the Chemokine Family. J. Exp. Med. July 1992, Vol. 176, pages 59-65.	1-21
A	US 5,401,629 A (HARPOLD ET AL) 28 March 1995 (28/03/95), see entire document, column 1, line 6-14.	22-35
X	SCHALL et al. A Human T Cell-specific Molecule is a Member of a New Gene Family. J. Immunol. 01 August 1988, Vol. 141, No. 3, pages 1018-1025, especially pages 1019-1020.	34

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06568

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 5-6, 12-14, 24
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/06568

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/7.2, 7.21, 69.1, 70.1, 71.1, 71.2, 172.3, 325, 252.3, 320.1

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, MEDLINE, BIOSIS, CAPLUS, EMBASE

search terms: eosinophil eotaxin receptor, polypeptide or protein, nucleic acid, DNA, production, isolation, method or assay for ligand detection.

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

Claims 5-6, 12-14 and 24 are unsearchable to the extent that they require reference to the specified sequences from the sequence listing. Because Applicant has not furnished a machine-readable copy of the sequence listing, no meaningful search of the sequences per se can be carried out by this Authority. However, the subject matter of the claims has been searched to the extent possible with reference to the balance of the description.